The initiative forges a new, more effective approach to research with great potential for widespread application.
This new brand of team science and unprecedented integration and comprehensiveness — from prevention through survivorship — paves the way for eventual extension of its novel approaches to all cancer research programs at MD Anderson and ultimately worldwide.
To launch the program, a panel of 25 internal and external experts meticulously reviewed proposals from across the institution and selected six projects that focus on eight cancers. These are acute myeloid leukemia/myelodysplastic syndrome, chronic lymphocytic leukemia, lung cancer, melanoma, prostate cancer, and triple-negative breast/high-grade serous ovarian cancers.
Today’s cancer experts focus increasingly on specific mutations that drive and sustain each disease and how best to target and disable them. Because certain genetic mutations arise in multiple cancers, discoveries in one cancer can lead to advances against others.
MD Anderson will use these new and promising research blueprints as the program continues groundbreaking studies — and results — for all cancers.